Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma.
Ann Hepatol
; 14(5): 756-61, 2015.
Article
in En
| MEDLINE
| ID: mdl-26256907
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Virus Activation
/
Antineoplastic Combined Chemotherapy Protocols
/
Cholestasis
/
Lymphoma, Large B-Cell, Diffuse
/
Hepatitis C
/
Hepacivirus
/
Rituximab
Type of study:
Diagnostic_studies
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
Ann Hepatol
Journal subject:
GASTROENTEROLOGIA
Year:
2015
Document type:
Article
Affiliation country:
Italy
Country of publication:
Mexico